PATHOGENESIS AND THERAPY OF TROPICAL DISEASES

该计划的主要目标是进行流行病学，临床 和免疫学研究来扩大我们对发病机理的了解， 治疗和控制血吸虫病、利什曼病和持续性 传染病。 UFBA/UFC/UFRN/FIOCRUZ热带医学研究 CENTER Consortium将汇集来自世界各地的调查人员的专业知识， 巴西东北部。 TMRC将加强我们与 美国科学家，并将为美国提供机会 研究人员对热带疾病进行研究。 重大疾病 巴西东北部贫困地区流行的疾病包括： 利什曼病、血吸虫病、丝虫病、恰加斯病、麻风病， 疟疾、肠道感染引起的腹泻和蠕虫病。 总的纲领性主题是细胞因子在发病机制中的作用 以及治疗和控制疾病的新方法 血吸虫病、利什曼病和持续腹泻。 项目一 “曼氏血吸虫：肝脾、HLA和T细胞应答”将决定 HLA Ⅱ类基因对细胞免疫发育的影响 对粗的和确定的疟原虫抗原的反应，导致 发展为严重的肝脾血吸虫病。 项目二. “内脏利什曼病的自然史和人类免疫遗传学， 巴西塞阿拉和北格兰德河”将表征免疫学和 与耐药或易感性相关的遗传因素 内脏利什曼病的发展 项目三.“免疫调节 利什曼病”将决定免疫事件发生后早期 利什曼原虫与巨噬细胞的接触，细胞因子（GM-CSF）的作用 和IL-12）作为疫苗佐剂， 与用IL-12治疗皮肤利什曼病相关的反应 与五价锑化合。 项目四.“细胞因子的作用， 细胞免疫决定因素和治疗的新方法 隐孢子虫高风险人群的持续性腹泻， 肠聚集性大肠大肠杆菌和其他肠道感染”将定义 肠细胞因子和细胞免疫在生理性 隐孢子虫E.大肠杆菌和其他腹泻 疾病，并检查新的，基于功能的方法， 疗法

The main objective of this program is to perform epidemiological, clinical and immunological studies to expand our knowledge of the pathogenesis, treatment and control of schistosomiasis, leishmaniasis and persistent diarrheal disease. The UFBA/UFC/UFRN/FIOCRUZ TROPICAL MEDICINE RESEARCH CENTER Consortium will bring together the expertise of investigators from the Northeast of Brazil. The TMRC will increase our collaboration with American scientists and will provide opportunities for United States investigators to conduct research on tropical disease. Major diseases which are endemic in the impoverished Northeast of Brazil include: leishmaniasis, schistosomiasis, filariasis, Chagas' disease, leprosy, malaria, diarrhea due to enteric infections and helminthiasis. The overall programmatic theme is the role of cytokines in pathogenesis and disease expression and novel approaches to treatment and control of schistosomiasis, leishmaniasis and persistent diarrhea. Project I. "S.mansoni: Hepatosplenism, HLA and T cell responses" will determine the influence of HLA class II alleles on the development of cellular immune responses to crude and defined schistosoma antigens that led to the development of severe hepatosplenism schistosomiasis. Project II. "Natural history and human immunogenetics of visceral leishmaniasis in Ceara and Rio Grande do Norte, Brazil" will characterize immunological and genetic factors associated with resistance or susceptibility to the development of visceral leishmaniasis. Project III. "Immunoregulation in leishmaniasis" will determine immunological events occurring early after the contact of leishmania with macrophages, the role of cytokines (GM-CSF and IL-12) as vaccine adjuvants and the immunological and clinical responses related to treatment of cutaneous leishmaniasis with IL-12 in combination with pentavalent antimony. Project IV. "Role of Cytokines, Cellular Immunologic Determinants and New Approaches to Treating Persistent diarrhea in population at high risk for Crytosporidium, enteroaggregative E. coli and other enteric infections" will define the role of enteric cytokines and cellular immunity in the physiologic derangements in persistent cryptosporidal, E. coli and other diarrhea illnesses and to examine novel, function-based approaches to their therapy.